Firocoxib 57 Mg Chewable

Verify with FDA CVM →

518 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
518
Total Reports
62
Deaths Reported
1200.0%
Death Rate

Active Ingredients

Firocoxib 57 Mg Chewable

Administration Routes

OralUnknownSubcutaneousOther

Species Affected

Dog 367
Unknown 112
Horse 32
Cat 4
Human 3

Most Affected Breeds

Unknown 120
Crossbred Canine/dog 30
Dog (unknown) 22
Shih Tzu 20
Schnauzer - Miniature 14
Spaniel - Cocker American 14
Dachshund (unspecified) 13
Chihuahua 13
Terrier - Jack Russell 12
Pug 11

Most Reported Reactions

Vomiting 130
Other abnormal test result NOS 86
Lethargy (see also Central nervous system depression in 'Neurological') 66
Diarrhoea 49
Elevated blood urea nitrogen (BUN) 46
Anorexia 46
Elevated creatinine 35
Elevated alanine aminotransferase (ALT) 35
Not eating 33
Death 32
Elevated serum alkaline phosphatase (SAP) 30
Containers, Damaged 27

Outcome Breakdown

Outcome Unknown
206 (50.6%)
Recovered/Normal
92 (22.6%)
Ongoing
44 (10.8%)
Died
35 (8.6%)
Euthanized
27 (6.6%)
Recovered with Sequela
3 (0.7%)

Data Summary

Metric Value
Total adverse event reports 518
Reports involving death 62
Case-fatality rate (reported events) 1200.0%
Distinct species in reports 5
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Firocoxib 57 Mg Chewable Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 518 adverse event reports referencing Firocoxib 57 Mg Chewable, including 62 reports in which the animal died — a 1200.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Firocoxib 57 Mg Chewable. Reported administration routes include Oral, Unknown, Subcutaneous, Other. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Firocoxib 57 Mg Chewable reports are Dog (367 reports), Unknown (112 reports), Horse (32 reports), with Dog accounting for the largest share. Within those species, Unknown (120), Crossbred Canine/dog (30), Dog (unknown) (22) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Firocoxib 57 Mg Chewable are Vomiting (130), Other abnormal test result NOS (86), Lethargy (see also Central nervous system depression in 'Neurological') (66), Diarrhoea (49). Of the 407 reports with a coded outcome, Outcome Unknown is the leading category at 50.6%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Firocoxib 57 Mg Chewable.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial